Mylan Pharmaceuticals Inc.
Rivastigmine
GenericID: 00378907093
NaN Reviews
đ Prescription Required
FORM
Patch
STRENGTH
QUANTITY
*Final prices are shown at checkout.
Don't have a prescription?
Do you already have an Rx?
How Medmind Works
1
Search for your medication
Find your prescription or over-the-counter medication using our comprehensive database.
2
Compare prices from multiple pharmacies
View prices from various pharmacies in your area to find the best deals.
3
Get your prescription filled
Choose your preferred pharmacy and get your medication at the best price.
TL;DR â Quick Summary
Key facts from the full medication guide below
đŠēWhat it's for
Rivastigmine transdermal system is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer s type (AD). (1.1) Mild-to-moderate dementia associated with Parkinson s disease (PD).
đHow to take it
Apply transdermal system on intact skin for a 24-hour period; replace with a new transdermal system every 24 hours. (2.1, 2.4) Initial Dose: Initiate treatment with 4.6 mg/24 hours rivastigmine transdermal system. (2.1) Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 9.5 mg/24 hours, which is the minimum effective dose. Following a minimum additional 4 weeks, may increase dosage to maximum dosage of 13.3 mg/24 hours.
âšī¸Common side effects
Rivastigmine transdermal system can cause gastrointestinal adverse reactions, including significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. The incidence and severity of these reactions are dose-related [see Adverse Reactions (6.1)].
â ī¸Serious risks
Hospitalization and, rarely, death have been reported due to application of multiple transdermal systems at same time. Ensure patients or caregivers receive instruction on proper dosing and administration. (5.1) Gastrointestinal Adverse Reactions: May include significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss, and may necessitate treatment interruption. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes.
đInteractions & cautions
Concomitant use with metoclopramide, beta-blockers, or cholinomimetics and anticholinergic medications is not recommended.
đĻStorage & missed dose
Rivastigmine Transdermal System is available as 4.6 mg/24 hours, 9.5 mg/24 hours or 13.3 mg/24 hours of rivastigmine. Rivastigmine Transdermal System 4.6 mg/24 hours Each transdermal system of 5 cm2 contains 9 mg rivastigmine, USP base with in vivo release rate of 4.6 mg/24 hours.
Ask MedMind
Questions answered from this medication guide. Sign in to personalize with your meds & labs.
Rivastigmine (Rivastigmine) Prices
Current MedMind pricing â no insurance required
Rivastigmine transdermal system is indicated for the treatment of dementia of the Alzheimer s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer s disease.
Rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with Parkinson s disease (PDD).
Apply transdermal system on intact skin for a 24-hour period; replace with a new transdermal system every 24 hours. (2.1, 2.4) Initial Dose: Initiate treatment with 4.6 mg/24 hours rivastigmine transdermal system. (2.1) Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 9.5 mg/24 hours, which is the minimum effective dose. Following a minimum additional 4 weeks, may increase dosage to maximum dosage of 13.3 mg/24 hours. (2.1) Mild-to-Moderate Alzheimer s Disease and Parkinson s Disease Dementia: Rivastigmine transdermal system 9.5 mg/24 hours or 13.3 mg/24 hours once daily. (2.1) Severe Alzheimer s Disease: Rivastigmine transdermal system 13.3 mg/24 hours once daily. (2.1) For treatment interruption longer than 3 days, retitrate dosage starting at 4.6 mg per 24 hours. (2.1) Consider dose adjustments in patients with (2.2): oMild-to-moderate hepatic impairment (8.6) oLow (less than 50 kg) body weight (8.7)
No fertility or reproduction studies of dermal rivastigmine have been conducted in animals. Rivastigmine had no effect on fertility or reproductive performance in rats at oral doses up to 1.1 mg/kg/day.
The effective dosage of rivastigmine transdermal system is 9.5 mg/24 hours or 13.3 mg/24 hours administered once per day; replace with a new transdermal system every 24 hours.
The effective dosage of rivastigmine transdermal system in patients with severe Alzheimer s disease is 13.3 mg/24 hours administered once per day; replace with a new transdermal system every 24 hours.
Patients treated with rivastigmine capsules or oral solution may be switched to rivastigmine transdermal system as follows: A patient who is on a total daily dose of less than 6 mg of oral rivastigmine can be switched to the 4.6 mg/24 hours rivastigmine transdermal system. A patient who is on a total daily dose of 6 mg to 12 mg of oral rivastigmine can be switched to the 9.5 mg/24 hours rivastigmine transdermal system. Instruct patients or caregivers to apply the first transdermal system on the day following the last oral dose.
Rivastigmine transdermal system is for transdermal use on intact skin. (a) Do not use the transdermal system if the pouch seal is broken or the transdermal system is cut, damaged, or changed in any way. (b) Apply the rivastigmine transdermal system once a day. Press down firmly for 30 seconds until the edges stick well when applying to clean, dry, hairless, intact healthy skin in a place that will not be rubbed against by tight clothing. Use the upper or lower back as the site of application because the transdermal system is less likely to be removed by the patient. If sites on the back are not accessible, apply the transdermal system to the upper arm or chest. Do not apply to a skin area where cream, lotion, or powder has recently been applied. (c) Do not apply to skin that is red, irritated, or cut. (d) Replace the rivastigmine transdermal system with a new transdermal system every 24 hours. Instruct patients to only wear 1 transdermal system at a time (remove the previous day s transdermal system before applying a new transdermal system) [see Warnings and Precautions (5.1), Overdosage (10)]. If a transdermal system falls off or if a dose is missed, apply a new transdermal system immediately, and then replace this transdermal system the following day at the usual application time. (e) Change the site of transdermal system application daily to minimize potential irritation, although a new transdermal system can be applied to the same general anatomic site (e.g., another spot on the upper back) on consecutive days. Do not apply a new transdermal system to the same location for at least 14 days. (f) May wear the transdermal system during bathing and in hot weather. Avoid long exposure to external heat sources (excessive sunlight, saunas, solariums). (g) Place used transdermal systems in the previously saved pouch and discard in the trash, away from pets or children. (h) Wash hands with soap and water after removing the transdermal system. In case of contact with eyes or if the eyes become red after handling the transdermal system, rinse immediately with plenty of water, and seek medical advice if symptoms do not resolve.
Rivastigmine Transdermal System is available as 4.6 mg/24 hours, 9.5 mg/24 hours or 13.3 mg/24 hours of rivastigmine. Each transdermal system of 5 cm2 contains 9 mg rivastigmine, USP base with in vivo release rate of 4.6 mg/24 hours. The round transdermal system consists of a peach-colored backing randomly printed with Rivastigmine 4.6 mg/24 hours in brown ink, a translucent adhesive layer, and a clear to slightly hazy oversized release liner that is slit and has small dimples surrounding the transdermal system. Each transdermal system also has a clear to slightly hazy oversized underlay and is contained in a square pouch. The pouch is imprinted with lot number and expiration date. Each transdermal system of 10 cm2 contains 18 mg rivastigmine, USP base with in vivo release rate of 9.5 mg/24 hours. The round transdermal system consists of a peach-colored backing randomly printed with Rivastigmine 9.5 mg/24 hours in brown ink, a translucent adhesive layer, and a clear to slightly hazy oversized release liner that is slit and has small dimples surrounding the transdermal system. Each transdermal system also has a clear to slightly hazy oversized underlay and is contained in a square pouch. The pouch is imprinted with lot number and expiration date. Each transdermal system of 15 cm2 contains 27 mg rivastigmine, USP base with in vivo release rate of 13.3 mg/24 hours. The round transdermal system consists of a peach-colored backing randomly printed with Rivastigmine 13.3 mg/24 hours in brown ink, a translucent adhesive layer, and a clear to slightly hazy oversized release liner that is slit and has small dimples surrounding the transdermal system. Each transdermal system also has a clear to slightly hazy oversized underlay and is contained in a square pouch. The pouch is imprinted with lot number and expiration date. Transdermal system: 4.6 mg/24 hours or 9.5 mg/24 hours or 13.3 mg/24 hours (3)
Rivastigmine transdermal system is contraindicated in patients with: known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see Description (11)] previous history of application-site reactions with rivastigmine transdermal system suggestive of allergic contact dermatitis [see Warnings and Precautions (5.3)]. Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions (6.2)]. Known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation. (4) History of application-site reactions with rivastigmine transdermal system suggestive of allergic contact dermatitis. (4, 6.2)
Hospitalization and, rarely, death have been reported due to application of multiple transdermal systems at same time. Ensure patients or caregivers receive instruction on proper dosing and administration. (5.1) Gastrointestinal Adverse Reactions: May include significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss, and may necessitate treatment interruption. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. (5.2) Application-site reactions may occur with the transdermal system form of rivastigmine. Discontinue treatment if application-site reactions spread beyond the transdermal system size, if there is evidence of a more intense local reaction (e.g., increasing erythema, edema, papules, vesicles), and if symptoms do not significantly improve within 48 hours after transdermal system removal. (5.3)
Medication errors with rivastigmine transdermal system have resulted in serious adverse reactions; some cases have required hospitalization, and rarely, led to death. The majority of medication errors have involved not removing the old transdermal system when putting on a new one and the use of multiple transdermal systems at one time. Instruct patients and their caregivers on important administration instructions for rivastigmine transdermal system [see Dosage and Administration (2.4)].
Rivastigmine transdermal system can cause gastrointestinal adverse reactions, including significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. The incidence and severity of these reactions are dose-related [see Adverse Reactions (6.1)]. For this reason, initiate treatment with rivastigmine transdermal system at a dose of 4.6 mg/24 hours and titrate to a dose of 9.5 mg/24 hours, and then to a dose of 13.3 mg/24 hours, if appropriate [see Dosage and Administration (2.1)]. If treatment is interrupted for more than 3 days because of intolerance, reinitiate rivastigmine transdermal system with the 4.6 mg/24 hours dose to reduce the possibility of severe vomiting and its potentially serious sequelae. A postmarketing report described a case of severe vomiting with esophageal rupture following inappropriate reinitiation of treatment of an oral formulation of rivastigmine without retitration after 8 weeks of treatment interruption. Inform caregivers to monitor for gastrointestinal adverse reactions and to inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than 3 days because of intolerance, the next dose should not be administered without contacting the physician regarding proper retitration.
Skin application-site reactions may occur with rivastigmine transdermal system. These reactions are not in themselves an indication of sensitization. However, use of rivastigmine transdermal system may lead to allergic contact dermatitis. Allergic contact dermatitis should be suspected if application-site reactions spread beyond the transdermal system size, if there is evidence of a more intense local reaction (e.g., increasing erythema, edema, papules, vesicles), and if symptoms do not significantly improve within 48 hours after transdermal system removal. In these cases, treatment should be discontinued [see Contraindications (4)]. In patients who develop application-site reactions to rivastigmine transdermal system, suggestive of allergic contact dermatitis and who still require rivastigmine, treatment should be switched to oral rivastigmine only after negative allergy testing and under close medical supervision. It is possible that some patients sensitized to rivastigmine by exposure to rivastigmine transdermal system may not be able to take rivastigmine in any form. There have been isolated postmarketing reports of patients experiencing disseminated allergic dermatitis when administered rivastigmine irrespective of the route of administration (oral or transdermal). In these cases, treatment should be discontinued [see Contraindications (4)]. Patients and caregivers should be instructed accordingly.
Cholinomimetics, including rivastigmine, may exacerbate or induce extrapyramidal symptoms. Worsening of parkinsonian symptoms, particularly tremor, has been observed in patients with dementia associated with Parkinson s disease who were treated with rivastigmine capsules.
Drugs that increase cholinergic activity are believed to have some potential for causing seizures. However, seizure activity also may be a manifestation of Alzheimer s disease.
Dementia may cause gradual impairment of driving performance or compromise the ability to use machinery. The administration of rivastigmine may also result in adverse reactions that are detrimental to these functions. During treatment with rivastigmine transdermal system, routinely evaluate the patient s ability to continue driving or operating machinery.
The following adverse reactions are described below and elsewhere in the labeling: Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.2)] Skin Reactions [see Warnings and Precautions (5.3)] Other Adverse Reactions from Increased Cholinergic Activity [see Warnings and Precautions (5.4)] Most common adverse reactions (less than 5% and higher than with placebo): Nausea, vomiting, and diarrhea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Rivastigmine transdermal system has been administered to 4516 patients with Alzheimer s disease during clinical trials worldwide. Of these, 3005 patients have been treated for at least 26 weeks, 1771 patients have been treated for at least 52 weeks, 974 patients have been treated for at least 78 weeks, and 24 patients have been treated for at least 104 weeks.
The following adverse reactions have been identified during post approval use of rivastigmine capsules, rivastigmine oral solution or rivastigmine transdermal system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac Disorders: Tachycardia, QTc prolongation, torsades de pointes Hepatobiliary Disorders: Abnormal liver function tests, hepatitis Nervous System Disorders: Parkinson s disease (worsening), seizure, tremor Psychiatric Disorders: nightmares Skin and Subcutaneous Tissue Disorders: Allergic dermatitis, application-site hypersensitivity, blister, disseminated allergic dermatitis, Stevens-Johnson syndrome, urticaria Vascular Disorders: Hypertension
Concomitant use with metoclopramide, beta-blockers, or cholinomimetics and anticholinergic medications is not recommended. (7.1, 7.2, 7.3)
Due to the risk of additive extra-pyramidal adverse reactions, the concomitant use of metoclopramide and rivastigmine transdermal system is not recommended.
Rivastigmine transdermal system may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine). Concomitant use of rivastigmine transdermal system with medications having these pharmacologic effects is not recommended unless deemed clinically necessary [see Warnings and Precautions (5.5) ].
Additive bradycardic effects resulting in syncope may occur when rivastigmine transdermal system is used concomitantly with beta-blockers, especially cardioselective beta-blockers (including atenolol). Concomitant use is not recommended when signs of bradycardia, including syncope are present.
There are no data on the presence of rivastigmine in human milk, the effects on the breastfed infant, or the effects of rivastigmine on milk production. Rivastigmine and its metabolites are excreted in rat milk following oral administration of rivastigmine; levels of rivastigmine plus metabolites in rat milk are approximately 2 times that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother s clinical need for rivastigmine transdermal system and any potential adverse effects on the breastfed infant from rivastigmine or from the underlying maternal condition.
Safety and effectiveness in pediatric patients have not been established. The use of rivastigmine transdermal system in pediatric patients (below 18 years of age) is not recommended.
Of the total number of patients in clinical studies of rivastigmine transdermal system, 88% were 65 years and over, while 55% were 75 years. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Increased exposure to rivastigmine was observed in patients with mild or moderate hepatic impairment with oral rivastigmine. Patients with mild or moderate hepatic impairment may be able to only tolerate lower doses [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)]. No data are available on the use of rivastigmine in patients with severe hepatic impairment.
Because rivastigmine blood levels vary with weight, careful titration and monitoring should be performed in patients with low or high body weights [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].
Overdose with rivastigmine transdermal system has been reported in the postmarketing setting [see Warnings and Precautions (5.1)]. Overdoses have occurred from application of more than one transdermal system at one time and not removing the previous day s transdermal system before applying a new transdermal system. The symptoms reported in these overdose cases are similar to those seen in cases of overdose associated with rivastigmine oral formulations. Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug. As rivastigmine has a plasma half-life of about 3.4 hours after transdermal system administration and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose the transdermal system should be immediately removed and no further transdermal system should be applied for the next 24 hours. As in any case of overdose, general supportive measures should be utilized. Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when coadministered with quaternary anticholinergics, such as glycopyrrolate. Additional symptoms associated with rivastigmine overdose are diarrhea, abdominal pain, dizziness, tremor, headache, somnolence, confusional state, hyperhidrosis, hypertension, hallucinations and malaise. Due to the short plasma elimination half-life of rivastigmine after transdermal system administration, dialysis (hemodialysis, peritoneal dialysis, or hemofiltration) would not be clinically indicated in the event of an overdose. In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. A fatal outcome has rarely been reported with rivastigmine overdose.
Rivastigmine transdermal system contains rivastigmine, a reversible cholinesterase inhibitor known chemically as (S)-3-[1-(Dimethylamino) ethyl]phenyl ethyl(methyl)carbamate. It has a molecular formula of C14H22N2O2 as the base and a molecular weight of 250.34 g/mol (as the base). Rivastigmine, USP is a viscous, clear, and colorless to yellow to very slightly brown liquid that is sparingly soluble in water and very soluble in ethanol, acetonitrile, n-octanol and ethyl acetate. The distribution coefficient at 37 C in n-octanol/phosphate buffer solution pH 7 is 4.27. Rivastigmine transdermal system is for transdermal administration. The transdermal system is a 4-layer laminate containing the backing layer, drug matrix, adhesive matrix and slit protective release liner (see Figure 1). The release liner is removed and discarded prior to use. Figure 1: Cross Section of the Rivastigmine Transdermal System Excipients within the formulation include acrylic adhesive, dimethicone, poly(butylmethacrylate, methylmethacrylate), silicone adhesive, and flexible polymer backing film printed with brown ink. The brown ink contains acrylic polymers, carbon black, iron oxides (yellow and red), polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, and sodium dioctyl sulfosuccinate. Rivastigmine transdermal systems are packaged with an additional piece of protective film below the system within each pouch. This piece of protective film is removed and discarded at the time of use.
Although the precise mechanism of action of rivastigmine is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that rivastigmine alters the course of the underlying dementing process.
After a 6-mg oral dose of rivastigmine in humans, anticholinesterase activity is present in cerebrospinal fluid for about 10 hours, with a maximum inhibition of about 60% 5 hours after dosing. In vitro and in vivo studies demonstrate that the inhibition of cholinesterase by rivastigmine is not affected by the concomitant administration of memantine, an N-methyl-D-aspartate receptor antagonist.
The effectiveness of the rivastigmine transdermal system in dementia of the Alzheimer s type and dementia associated with Parkinson s disease was based on the results of 3 controlled trials of rivastigmine transdermal system in patients with Alzheimer s disease (Studies 1, 2, and 3) (see below); 3 controlled trials of oral rivastigmine in patients with dementia of the Alzheimer s type; and 1 controlled trial of oral rivastigmine in patients with dementia associated with Parkinson s disease. See the prescribing information for oral rivastigmine for details of the four studies of oral rivastigmine. Mild-to-Moderate Alzheimer s Disease International 24-Week Study of Rivastigmine Transdermal System in Dementia of the Alzheimer s Type (Study 1) This study was a randomized double-blind, double dummy clinical investigation in patients with Alzheimer s disease [diagnosed by NINCDS-ADRDA and DSM-IV criteria, Mini-Mental Status Examination (MMSE) score greater than or equal to 10 and less than or equal to 20] (Study 1). The mean age of patients participating in this trial was 74 years with a range of 50 to 90 years. Approximately 67% of patients were women, and 33% were men. The racial distribution was Caucasian 75%, black 1%, Asian 9%, and other races 15%. The effectiveness of the rivastigmine transdermal system was evaluated in Study 1 using a dual outcome assessment strategy, evaluating for changes in both cognitive performance and overall clinical effect. The ability of the rivastigmine transdermal system to improve cognitive performance was assessed with the cognitive subscale of the Alzheimer s Disease Assessment Scale (ADAS-Cog), a multi-item instrument that has been extensively validated in longitudinal cohorts of Alzheimer s-disease patients. The ADAS-Cog examines selected aspects of cognitive performance, including elements of memory, orientation, attention, reasoning, language, and praxis. The ADAS-Cog scoring range is from 0 to 70, with higher scores indicating greater cognitive impairment. Elderly normal adults may score as low as 0 or 1, but it is not unusual for non-demented adults to score slightly higher. The ability of the rivastigmine transdermal system to produce an overall clinical effect was assessed using the Alzheimer s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). The ADCS-CGIC is a more standardized form of the Clinician's Interview-Based Impression of Change-Plus (CIBIC-Plus) and is also scored as a 7-point categorical rating; scores range from 1, indicating markedly improved, to 4, indicating no change, to 7, indicating marked worsening. In Study 1, 1195 patients were randomized to 1 of the following 4 treatments: rivastigmine transdermal system 9.5 mg/24 hours, rivastigmine transdermal system 17.4 mg/24 hours, rivastigmine capsules in a dose of 6 mg twice daily, or placebo. This 24-week study was divided into a 16-week titration phase followed by an 8-week maintenance phase. In the active treatment arms of this study, doses below the target dose were permitted during the maintenance phase in the event of poor tolerability. Figure 3 illustrates the time course for the change from baseline in ADAS-Cog scores for all 4 treatment groups over the 24-week study. At 24 weeks, the mean differences in the ADAS-Cog change scores for the rivastigmine-treated patients compared to the patients on placebo, were 1.8, 2.9, and 1.8 units for the rivastigmine transdermal system 9.5 mg/24 hours, rivastigmine transdermal system 17.4 mg/24 hours, and rivastigmine capsule 6 mg twice daily groups, respectively. The difference between each of these groups and placebo was statistically significant. Although a slight improvement was observed with the 17.4 mg/24 hours transdermal system compared to the 9.5 mg/24 hours transdermal system on this outcome measure, no meaningful difference between the two was seen on the global evaluation (see Figure 4). Figure 3: Time Course of the Change from Baseline in ADAS-Cog Score for Patients Observed at Each Time Point in Study 1 Figure 4 presents the distribution of patients scores on the ADCS-CGIC for all 4 treatment groups. At 24 weeks, the mean difference in the ADCS-CGIC scores for the comparison of patients in each of the rivastigmine-treated groups with the patients on placebo was 0.2 units. The difference between each of these groups and placebo was statistically significant. Figure 4: Distribution of ADCS-CGIC Scores for Patients Completing Study 1 International 48-Week Study of Rivastigmine Transdermal System in Dementia of the Alzheimer s Type (Study 2) This study was a randomized double-blind clinical investigation in patients with Alzheimer s disease [diagnosed by NINCDS-ADRDA and DSM-IV criteria, Mini-Mental State Examination (MMSE) score greater than or equal to 10 and less than or equal to 24] (Study 2). The mean age of patients participating in this trial was 76 years with a range of 50 to 85 years. Approximately 65% of patients were women and 35% were men. The racial distribution was approximately Caucasian 97%, black 2%, Asian 0.5%, and other races 1%. Approximately 27% of the patients were taking memantine throughout the entire duration of the study. Alzheimer s disease patients who received 24 to 48 weeks open-label treatment with rivastigmine transdermal system 9.5 mg/24 hours and who demonstrated functional and cognitive decline were randomized into treatment with either rivastigmine transdermal system 9.5 mg/24 hours or rivastigmine transdermal system 13.3 mg/24 hours in a 48-week, double-blind treatment phase. Functional decline was assessed by the investigator and cognitive decline was defined as a decrease in the MMSE score of greater than or equal to 2 points from the previous visit or a decrease of greater than or equal to 3 points from baseline. Study 2 was designed to compare the efficacy of rivastigmine transdermal system 13.3 mg/24 hours versus that of rivastigmine transdermal system 9.5 mg/24 hours during the 48-week, double-blind treatment phase. The ability of the rivastigmine transdermal system 13.3 mg/24 hours to improve cognitive performance over that provided by the rivastigmine transdermal system 9.5 mg/24 hours was assessed by the cognitive subscale of the Alzheimer s Disease Assessment Scale (ADAS-Cog) [see Clinical Studies (14)]. The ability of the rivastigmine transdermal system 13.3 mg/24 hours to improve overall function versus that provided by rivastigmine transdermal system 9.5 mg/24 hours was assessed by the instrumental subscale of the Alzheimer s Disease Cooperative Study Activities of Daily Living (ADCS-IADL). The ADCS-IADL subscale is composed of items 7 to 23 of the caregiver-based ADCS-ADL scale. The ADCS-IADL assesses activities, such as those necessary for communicating and interacting with other people, maintaining a household, and conducting hobbies and interests. A sum score is calculated by adding the scores of the individual items and can range from 0 to 56, with higher scores indicating less impairment. Out of a total of 1584 patients enrolled in the initial open-label phase of the study, 567 patients were classified as decliners and were randomized into the 48-week double-blind treatment phase of the study. Two hundred eighty-seven (287) patients entered the 9.5 mg/24 hours rivastigmine transdermal system treatment group and 280 patients entered the 13.3 mg/24 hours rivastigmine transdermal system treatment group. Figure 5 illustrates the time course for the mean change from double-blind baseline in ADCS-IADL scores for each treatment group over the course of the 48-week treatment phase of the study. Decline in the mean ADCS-IADL score from the double-blind baseline for the Intent to Treat-Last Observation Carried Forward (ITT-LOCF) analysis was less at each timepoint in the 13.3 mg/24 hour rivastigmine transdermal system treatment group than in the 9.5 mg/24 hours rivastigmine transdermal system treatment group. The 13.3 mg/24 hours dose was statistically significantly superior to the 9.5 mg/24 hours dose at weeks 16, 24, 32, and 48 (primary endpoint). Figure 6 illustrates the time course for the mean change from double-blind baseline in ADAS-Cog scores for both treatment groups over the 48-week treatment phase. The between-treatment group difference for rivastigmine transdermal system 13.3 mg/24 hours versus rivastigmine transdermal system 9.5 mg/24 hours was nominally statistically significant at week 24 (p = 0.027), but not at week 48 (p = 0.227), which was the primary endpoint. Figure 5: Time Course of the Change From Double-Blind Baseline in ADCS-IADL Score for Patients Observed at Each Time Point in Study 2 Figure 6: Time Course of the Change From Double-Blind Baseline in ADAS-Cog Score for Patients Observed at Each Time Point in Study 2 Severe Alzheimer s Disease 24-Week United States Study With Rivastigmine Transdermal System in Severe Alzheimer s Disease (Study 3) This was a 24-week randomized double-blind, clinical investigation in patients with severe Alzheimer s disease [diagnosed by NINCDS-ADRDA and DSM-IV criteria, Mini-Mental State Examination (MMSE) score greater than or equal to 3 and less than or equal to 12]. The mean age of patients participating in this trial was 78 years with a range of 51 to 96 years with 62% aged greater than 75 years. Approximately 65% of patients were women and 35% were men. The racial distribution was approximately Caucasian 87%, black 7%, Asian 1%, and other races 5%. Patients on a stable dose of memantine were permitted to enter the study. Approximately 61% of the patients in each treatment group were taking memantine throughout the entire duration of the study. The study was designed to compare the efficacy of rivastigmine transdermal system 13.3 mg/24 hours versus that of rivastigmine transdermal system 4.6 mg/24 hours during the 24-week double-blind treatment phase. The ability of the 13.3 mg/24 hours rivastigmine transdermal system to improve cognitive performance versus that provided by the 4.6 mg/24 hours rivastigmine transdermal system was assessed with the Severe Impairment Battery (SIB) which uses a validated 40-item scale developed for the evaluation of the severity of cognitive dysfunction in more advanced AD patients. The domains assessed included social interaction, memory, language, attention, orientation, praxis, visuospatial ability, construction, and orienting to name. The SIB was scored from 0 to 100, with higher scores reflecting higher levels of cognitive ability. The ability of the 13.3 mg/24 hours rivastigmine transdermal system to improve overall function versus that provided by the 4.6 mg/24 hours rivastigmine transdermal system was assessed with the Alzheimer s Disease Cooperative Study-Activities of Daily Living Severe Impairment Version (ADCS-ADL-SIV) which is a caregiver-based ADL scale composed of 19 items developed for use in clinical studies of dementia. It is designed to assess the patient s performance of both basic and instrumental activities of daily living, such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, and making judgments and decisions. A sum score is calculated by adding the scores of the individual items and can range from 0 to 54, with higher scores indicating less functional impairment. In this study, 716 patients were randomized into one of the following treatments: rivastigmine transdermal system 13.3 mg/24 hours or rivastigmine transdermal system 4.6 mg/24 hours in a 1:1 ratio. This 24-week study was divided into an 8-week titration phase followed by a 16-week maintenance phase. In the active treatment arms of this study, temporary dose adjustments below the target dose were permitted during the titration and maintenance phase in the event of poor tolerability. Figure 7 illustrates the time course for the mean change from baseline SIB scores for each treatment group over the course of the 24-week treatment phase of the study. Decline in the mean SIB score from the baseline for the Modified Full Analysis Set (MFAS)-Last Observation Carried Forward (LOCF) analysis was less at each timepoint in the 13.3 mg/24 hours rivastigmine transdermal system treatment group than in the 4.6 mg/24 hours rivastigmine transdermal system treatment group. The 13.3 mg/24 hours dose was statistically significantly superior to the 4.6 mg/24 hours dose at weeks 16 and 24 (primary endpoint). Figure 8 illustrates the time course for the mean change from baseline in ADCS-ADL-SIV scores for each treatment group over the course of the 24-week treatment phase of the study. Decline in the mean ADCS-ADLSIV score from baseline for the MFAS-LOCF analysis was less at each timepoint in the 13.3 mg/24 hours rivastigmine transdermal system treatment group than in the 4.6 mg/24 hours rivastigmine transdermal system treatment group. The 13.3 mg/24 hours dose was statistically significantly superior to the 4.6 mg/24 hours dose at weeks 16 and 24 (primary endpoint). Figure 7: Time Course of the Change From Baseline in SIB Score for Patients Observed at Each Time Point (Modified Full Analysis Set LOCF) Figure 8: Time Course of the Change From Baseline in ADCS-ADL-SIV Score for Patients Observed at Each Time Point (Modified Full Analysis Set LOCF)
Rivastigmine Transdermal System is available as 4.6 mg/24 hours, 9.5 mg/24 hours or 13.3 mg/24 hours of rivastigmine. Rivastigmine Transdermal System 4.6 mg/24 hours Each transdermal system of 5 cm2 contains 9 mg rivastigmine, USP base with in vivo release rate of 4.6 mg/24 hours. The round transdermal system consists of a peach-colored backing randomly printed with Rivastigmine 4.6 mg/24 hours in brown ink, a translucent adhesive layer, and a clear to slightly hazy oversized release liner that is slit and has small dimples surrounding the transdermal system. Each transdermal system also has a clear to slightly hazy oversized underlay and is contained in a square pouch. The pouch is imprinted with lot number and expiration date. They are available as follows: NDC 0378-9070-93carton containing 30 transdermal systems Rivastigmine Transdermal System 9.5 mg/24 hours Each transdermal system of 10 cm2 contains 18 mg rivastigmine, USP base with in vivo release rate of 9.5 mg/24 hours. The round transdermal system consists of a peach-colored backing randomly printed with Rivastigmine 9.5 mg/24 hours in brown ink, a translucent adhesive layer, and a clear to slightly hazy oversized release liner that is slit and has small dimples surrounding the transdermal system. Each transdermal system also has a clear to slightly hazy oversized underlay and is contained in a square pouch. The pouch is imprinted with lot number and expiration date. They are available as follows: NDC 0378-9071-93carton containing 30 transdermal systems Rivastigmine Transdermal System 13.3 mg/24 hours Each transdermal system of 15 cm2 contains 27 mg rivastigmine, USP base with in vivo release rate of 13.3 mg/24 hours. The round transdermal system consists of a peach-colored backing randomly printed with Rivastigmine 13.3 mg/24 hours in brown ink, a translucent adhesive layer, and a clear to slightly hazy oversized release liner that is slit and has small dimples surrounding the transdermal system. Each transdermal system also has a clear to slightly hazy oversized underlay and is contained in a square pouch. The pouch is imprinted with lot number and expiration date. They are available as follows: NDC 0378-9072-93carton containing 30 transdermal systems Store at 20 to 25 C (68 to 77 F) [See USP Controlled Room Temperature]. Keep rivastigmine transdermal system in the individual sealed pouch until use. Each pouch contains 1 transdermal system. Used systems should be folded, with the adhesive surfaces pressed together, and discarded safely.
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Importance of Correct Usage Inform patients or caregivers of the importance of applying the correct dose on the correct part of the body. They should be instructed to rotate the application site in order to minimize skin irritation. The same site should not be used within 14 days. The previous day s transdermal system must be removed before applying a new transdermal system to a different skin location. Rivastigmine transdermal system should be replaced every 24 hours and the time of day should be consistent. It may be helpful for this to be part of a daily routine, such as the daily bath or shower. Only 1 transdermal system should be worn at a time [see Dosage and Administration (2.4), Warnings and Precautions (5.1)]. Instruct patients or caregivers to avoid exposure of the transdermal system to external heat sources (excessive sunlight, saunas, solariums) for long periods of time. Instruct patients who have missed a dose to apply a new transdermal system immediately. They may apply the next transdermal system at the usual time the next day. Instruct patients to not apply 2 transdermal systems to make up for 1 missed. Inform the patient or caregiver to contact the physician for retitration instructions if treatment has been interrupted. Discarding Used Transdermal Systems Instruct patients or caregivers to fold the transdermal system in half after use, return the used transdermal system to its original pouch, and discard it out of the reach and sight of children and pets. They should also be informed that drug still remains in the transdermal system after 24-hour usage. They should be instructed to avoid eye contact and to wash their hands after handling the transdermal system. In case of accidental contact with the eyes, or if their eyes become red after handling the transdermal system, they should be instructed to rinse immediately with plenty of water and to seek medical advice if symptoms do not resolve [see Dosage and Administration (2.4)]. Gastrointestinal Adverse Reactions Inform patients or caregivers of the potential gastrointestinal adverse reactions, such as nausea, vomiting, and diarrhea, including the possibility of dehydration due to these symptoms. Explain that rivastigmine transdermal system may affect the patient s appetite and/or the patient s weight. Patients and caregivers should be instructed to look for these adverse reactions, in particular when treatment is initiated or the dose is increased. Instruct patients and caregivers to inform a physician if these adverse reactions persist [see Warnings and Precautions (5.2)]. Skin Reactions Inform patients or caregivers about the potential for allergic contact dermatitis reactions to occur. Patients or caregivers should be instructed to inform a physician if application-site reactions spread beyond the transdermal system size, if there is evidence of a more intense local reaction (e.g., increasing erythema, edema, papules, vesicles) and if symptoms do not significantly improve within 48 hours after transdermal system removal [see Warnings and Precautions (5.3)]. Concomitant Use of Drugs With Cholinergic Action Inform patients or caregivers that while wearing rivastigmine transdermal system, patients should not be taking rivastigmine capsules or rivastigmine oral solution or other drugs with cholinergic effects [see Warnings and Precautions (5.4)]. Pregnancy Advise patients to notify their healthcare provider if they are pregnant or plan to become pregnant.
Rivastigmine Transdermal System (riv a stig meen) What is the most important information I should know about rivastigmine transdermal system? Rivastigmine transdermal system is for skin use only. What is rivastigmine transdermal system? Rivastigmine transdermal system is a prescription medicine used to treat: Mild, moderate, and severe memory problems (dementia) associated with Alzheimer s disease. Mild-to-moderate memory problems (dementia) associated with Parkinson s disease (PD). Based on clinical trials conducted over 6 to 12 months, rivastigmine transdermal system was shown to help with cognition which includes (memory, understanding communication, and reasoning) and with doing daily tasks. Rivastigmine transdermal system does not work the same in all people. Some people treated with rivastigmine transdermal system may: Seem much better Get better in small ways or stay the same Get worse but slower than expected Not change and then get worse as expected Some patients will not benefit from treatment with rivastigmine transdermal system. Rivastigmine transdermal system does not cure Alzheimer s disease. All patients with Alzheimer s disease get worse over time. Rivastigmine transdermal system comes as a transdermal system that delivers rivastigmine (the medicine in rivastigmine transdermal system) through the skin. It is not known if rivastigmine transdermal system is safe or effective in children under 18 years of age. Who should not use rivastigmine transdermal system? Do not use rivastigmine transdermal system if you: are allergic to rivastigmine, carbamate derivatives, or any of the ingredients in rivastigmine transdermal system. See the end of this leaflet for a complete list of ingredients in rivastigmine transdermal system. have had a skin reaction that: ospread beyond the rivastigmine transdermal system size ohad blisters, increased skin redness, or swelling odid not get better within 48 hours after you removed the rivastigmine transdermal system Ask your healthcare provider if you are not sure if you should use rivastigmine transdermal system. What should I tell my healthcare provider before using rivastigmine transdermal system? Before you use rivastigmine transdermal system, tell your healthcare provider if you: have or have had a stomach ulcer are planning to have surgery have or have had problems with your heart have problems passing urine have or have had seizures have problems with movement (tremors) have asthma or breathing problems have a loss of appetite or are losing weight have had a skin reaction to rivastigmine (the medicine in rivastigmine transdermal system) in the past have any other medical conditions are pregnant or plan to become pregnant. It is not known if the medicine in rivastigmine transdermal system will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant. are breastfeeding or plan to breastfeed. It is not known if the medicine in rivastigmine transdermal system passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take rivastigmine transdermal system. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take: a medicine used to treat inflammation [nonsteroidal anti-inflammatory drugs (NSAIDs)] other medicines used to treat Alzheimer s or Parkinson s disease an anticholinergic medicine, such as an allergy or cold medicine, a medicine to treat bladder or bowel spasms, or certain asthma medicines, or certain medicines to prevent motion or travel sickness metoclopramide, a drug given to relieve symptoms of nausea, gastroesophageal reflux disease (GERD), or nausea and vomiting after surgery or chemotherapy treatment If you are undergoing surgery while using rivastigmine transdermal system, inform your doctor because rivastigmine transdermal system may exaggerate the effects of anesthesia, or the effects of a beta-blocker, a type of medicine given for high blood pressure, heart disease, and other medical conditions Ask your healthcare provider if you are not sure if your medicine is one listed above. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. How should I use rivastigmine transdermal system? Use rivastigmine transdermal system exactly as your healthcare provider tells you to use it. Rivastigmine transdermal system comes in 3 different dosage strengths. Your healthcare provider may change your dose as needed. Wear only 1 rivastigmine transdermal system at a time. Rivastigmine transdermal system is for skin use only. Only apply rivastigmine transdermal system to healthy skin that is clean, dry, hairless, and free of redness, irritation, burns or cuts. Avoid applying rivastigmine transdermal system to areas on your body that will be rubbed against tight clothing. Do not apply rivastigmine transdermal system to skin that has cream, lotion, or powder on it. Change your rivastigmine transdermal system every 24 hours at the same time of day. You may write the date and time you put on the rivastigmine transdermal system with a ballpoint pen before applying the transdermal system to help you remember when to remove it. Change your application site every day to avoid skin irritation. You can use the same area, but do not use the exact same spot for at least 14 days after your last application. Check to see if the rivastigmine transdermal system has become loose when you are bathing, swimming, or showering. Rivastigmine transdermal system is designed to deliver medication during the time it is worn. If your rivastigmine transdermal system falls off before its usual replacement time, put on a new rivastigmine transdermal system right away. Replace the new transdermal system the next day at the same time as usual. Do not use overlays, bandages, or tape to secure a rivastigmine transdermal system that has become loose or try to reapply a rivastigmine transdermal system that has fallen off. If you miss a dose or forget to change your rivastigmine transdermal system apply your next rivastigmine transdermal system as soon as you remember. Do not apply 2 rivastigmine transdermal systems to make up for the missed dose. If you miss more than 3 doses of applying rivastigmine transdermal system, call your healthcare provider before putting on a new rivastigmine transdermal system. You may need to restart rivastigmine transdermal system at a lower dose. Always remove the old rivastigmine transdermal system from the previous day before you apply a new one. Having more than 1 rivastigmine transdermal system on your body at the same time can cause you to get too much medicine. If you accidentally use more than 1 rivastigmine transdermal system at a time, call your healthcare provider right away. If you are unable to reach your healthcare provider, call your local Poison Control Center at 1-800-222-1222 or go to the nearest hospital emergency room right away. What should I avoid while using rivastigmine transdermal system? Do not touch your eyes after you touch the rivastigmine transdermal system. In case of accidental contact with your eyes or if your eyes become red after handling the transdermal system, rinse immediately with plenty of water and seek medical advice if symptoms do not resolve. Rivastigmine transdermal system can cause drowsiness, dizziness, weakness, or fainting. Do not drive, operate heavy machinery, or do other dangerous activities until you know how rivastigmine transdermal system affects you. Avoid exposure to heat sources, such as excessive sunlight, saunas, or sunrooms for long periods of time. What are the possible side effects of rivastigmine transdermal system? Rivastigmine transdermal system may cause serious side effects, including: Medication overdose. Hospitalization and rarely death may happen when people accidently wear more than 1 transdermal system at the same time. It is important that the old rivastigmine transdermal system be removed before you apply a new one. Do not wear more than 1 rivastigmine transdermal system at a time. Stomach or bowel (intestinal) problems, including: onausea ovomiting odiarrhea odehydration oloss of appetite oweight loss obleeding in your stomach (ulcers) Skin reactions. Some people have had a serious skin reaction called allergic contact dermatitis (ACD) when using rivastigmine transdermal system. Stop using rivastigmine transdermal system and call your healthcare provider right away if you experience reactions that spread beyond the transdermal system size, are intense in nature and do not improve within 48 hours after the transdermal system is removed. Symptoms of ACD may be intense and include: oitching, redness, swelling, warmth or tenderness of the skin opeeling or blistering of the skin that may ooze, drain or crust over Heart problems Seizures Problems with movement (tremors) The most common side effects of rivastigmine transdermal system include: depression headache anxiety dizziness stomach pain urinary tract infections muscle weakness tiredness trouble sleeping Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rivastigmine transdermal system. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. How should I store rivastigmine transdermal system? Store rivastigmine transdermal system at 68 to 77 F (20 to 25 C). Keep rivastigmine transdermal system in the sealed pouch until ready to use. Keep rivastigmine transdermal system and all medicines out of the reach of children. General information about the safe and effective use of rivastigmine transdermal system. Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use rivastigmine transdermal system for a condition for which it was not prescribed. Do not give rivastigmine transdermal system to other people, even if they have the same symptoms you have. It may harm them. This Patient Information leaflet summarizes the most important information about rivastigmine transdermal system. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about rivastigmine transdermal system that is written for health professionals. For more information, go to Mylan.com or call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). What are the ingredients of rivastigmine transdermal system? Active ingredient: rivastigmine Excipients include: acrylic adhesive, dimethicone, poly(butylmethacrylate, methylmethacrylate), silicone adhesive, and flexible polymer backing film printed with brown ink. The brown ink contains acrylic polymers, carbon black, iron oxides (yellow and red), polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, and sodium dioctyl sulfosuccinate. Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A. This Patient Information has been approved by the U.S. Food and Drug Administration.
Rivastigmine Transdermal System(riv a stig meen) You will need the following supplies (See Figure A): Rivastigmine transdermal system is supplied in cartons containing 30 transdermal systems (See Figure A) Figure A Rivastigmine transdermal system is a thin, peach, plastic transdermal system that sticks to the skin. Each rivastigmine transdermal system is sealed in a pouch that protects it until you are ready to put it on (See Figure A). Only 1 rivastigmine transdermal system should be worn at a time. Do not apply more than 1 rivastigmine transdermal system at a time to the body. Do not open the pouch or remove the rivastigmine transdermal system until you are ready to apply it. Using rivastigmine transdermal system: Step 1. Choose an area to apply the rivastigmine transdermal system (See Figure B). Instructions for Caregivers: Apply rivastigmine transdermal system to the upper or lower back if it is likely that the patient will remove it. If this is not a concern, the rivastigmine transdermal system can be applied instead to the upper arm or chest. Do not apply the rivastigmine transdermal system to areas where it can be rubbed off by tight clothing or belts. Only apply the rivastigmine transdermal system to healthy skin that is clean, dry, hairless, and free of redness, irritation, burns or cuts. Figure B The diagram represents areas on the body where rivastigmine transdermal system may be applied. Only 1 transdermal system should be worn at a time. Do not apply multiple transdermal systems to the body. Step 2. Remove the rivastigmine transdermal system from the pouch (See Figure C). Carefully cut the pouch along the dotted line to open and remove the rivastigmine transdermal system. Save the pouch for later use. Rivastigmine transdermal systems are packaged with an additional piece of protective film below the system within each pouch. This piece of protective film should be removed and discarded at the time of use. Figure C Do not cut or fold the rivastigmine transdermal system itself. Step 3. Remove 1 side of the adhesive liner (See Figure D). A protective liner covers the sticky (adhesive) side of the rivastigmine transdermal system. Peel off 1 side of the protective liner. Do not touch the sticky part of the rivastigmine transdermal system with your fingers. Figure D Step 4. Apply the rivastigmine transdermal system to your skin (See Figure E). Apply the sticky (adhesive) side of the rivastigmine transdermal system to your chosen area of skin and then peel off the other side of the protective release liner. Figure E Press down on the rivastigmine transdermal system firmly for 30 seconds to make sure that the edges stick to your skin (See Figure F). Figure F Step 5: Wash your hands with soap and water right away. Note: If your rivastigmine transdermal system falls off, select a new area, and repeat Steps 2 to 5 to apply a new rivastigmine transdermal system. Be sure to replace the new rivastigmine transdermal system the next day at the same time as usual. Removing your rivastigmine transdermal system: Step 6. Remove the rivastigmine transdermal system from the skin (See Figure G). Gently pull on 1 edge of the rivastigmine transdermal system to remove it from your skin. Figure G Throwing away the used rivastigmine transdermal system: Step 7. Throw away the used rivastigmine transdermal system (See Figure H). Fold the used rivastigmine transdermal system in half (with the sticky sides together) and put it back into the pouch that you saved. Figure H Throw away the used rivastigmine transdermal system safely and out of the reach of children and pets. Some medicine stays in the transdermal system for 24 hours after you use it and should be folded together (sticky side together) and safely thrown away. Do not try to re-use rivastigmine transdermal systems. Step 8: Wash your hands with soap and water right away. After you remove the rivastigmine transdermal system, if any adhesive remains on your skin, you can use soap and water or an oil-based substance (such as baby oil) to remove the adhesive. Alcohol or other dissolving liquids (such as nail polish remover) should not be used. This Instructions for Use have been approved by the U.S. Food and Drug Administration. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Revised: 9/2024RIVA:R5
Contains 30 Systems Rx only NDC 0378-9070-93 Rivastigmine Transdermal System Each System Delivers 4.6 mg/24 hours Each 5 cm2 system contains 9 mg rivastigmine, USP to provide 4.6 mg rivastigmine every 24 hours. Keep out of the reach of children. FOR TRANSDERMAL USE ONLY. Inactive components: acrylic adhesive, dimethicone, poly(butylmethacrylate, methylmethacrylate), silicone adhesive, and flexible polymer backing film printed with brown ink. The brown ink contains acrylic polymers, carbon black, iron oxides (yellow and red), polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, and sodium dioctyl sulfosuccinate. Apply patch immediately after removal from pouch. Do not store unpouched. Do not use any patch that is damaged or shows signs of tampering. Store at 20 to 25 C (68 to 77 F). [See USP Controlled Room Temperature.] Dosage and Administration: See package insert. Mylan.com Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. M9070:93:30C:R3 Discarding Rivastigmine Transdermal System Every 24 hours you should remove the old patch and apply a new patch. 1.Fold the used patch in half with the sticky side inwards, and place in its original pouch. 2.Discard patch safely out of the reach of children. Wash hands with soap and water. For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).
Contains 30 Systems Rx only NDC 0378-9071-93 Rivastigmine Transdermal System Each System Delivers 9.5 mg/24 hours Each 10 cm2 system contains 18 mg rivastigmine, USP to provide 9.5 mg rivastigmine every 24 hours. Keep out of the reach of children. FOR TRANSDERMAL USE ONLY. Inactive components: acrylic adhesive, dimethicone, poly(butylmethacrylate, methylmethacrylate), silicone adhesive, and flexible polymer backing film printed with brown ink. The brown ink contains acrylic polymers, carbon black, iron oxides (yellow and red), polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, and sodium dioctyl sulfosuccinate. Apply patch immediately after removal from pouch. Do not store unpouched. Do not use any patch that is damaged or shows signs of tampering. Store at 20 to 25 C (68 to 77 F). [See USP Controlled Room Temperature.] Dosage and Administration: See package insert. Mylan.com Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. M9071:93:30C:R4 Discarding Rivastigmine Transdermal System Every 24 hours you should remove the old patch and apply a new patch. 1.Fold the used patch in half with the sticky side inwards, and place in its original pouch. 2.Discard patch safely out of the reach of children. Wash hands with soap and water. For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).
Contains 30 Systems Rx only NDC 0378-9072-93 Rivastigmine Transdermal System Each System Delivers 13.3 mg/24 hours Each 15 cm2 system contains 27 mg rivastigmine, USP to provide 13.3 mg rivastigmine every 24 hours. Keep out of the reach of children. FOR TRANSDERMAL USE ONLY. Inactive components: acrylic adhesive, dimethicone, poly(butylmethacrylate, methylmethacrylate), silicone adhesive, and flexible polymer backing film printed with brown ink. The brown ink contains acrylic polymers, carbon black, iron oxides (yellow and red), polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, and sodium dioctyl sulfosuccinate. Apply patch immediately after removal from pouch. Do not store unpouched. Do not use any patch that is damaged or shows signs of tampering. Store at 20 to 25 C (68 to 77 F). [See USP Controlled Room Temperature.] Dosage and Administration: See package insert. Mylan.com Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. M9072:93:30C:R4 Discarding Rivastigmine Transdermal System Every 24 hours you should remove the old patch and apply a new patch. 1.Fold the used patch in half with the sticky side inwards, and place in its original pouch. 2.Discard patch safely out of the reach of children. Wash hands with soap and water. For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).
Other Manufacturers
Max Quantity Is Exceeding For This Order
Prescription Required
Macleods
Rivastigmine
Exelon
4.5 mg
$28.00
Max Quantity Is Exceeding For This Order
Prescription Required
Dr. Reddy's
Rivastigmine
Exelon
3 mg
$17.00
